Concepedia
Statistics
Publications
44
Citations
3.3K
H-Index
28
Active since
1972
Affiliations
Boehringer Ingelheim (Germany)(Current)
ETH Zurich
Pharmazeutische Fabrik Dr. Reckeweg (Germany)
Heidelberg University
Max Planck Institute for Medical Research
H. Wieland is an author at Boehringer Ingelheim (Germany) specializing in pharmacology, medicine, and neuropharmacology.
Publications per year
1972–2018
A single histidine in GABAA receptors is essential for benzodiazepine agonist binding.
H. Wieland, Hartmut Lüddens, P. H. Seeburg · Journal of Biological Chemistry · 1992 · 451 citations · Full text
Medicine, Neuroscience, Pharmacology +17
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
K Rudolf, Wolfgang Eberlein, Wolfhard Engel et al. · European Journal of Pharmacology · 1994 · 374 citations
Medicine, Neuroscience, Pharmacology +7
Cloning, pharmacological characteristics and expression pattern of the rat GABA<sub>A</sub> receptor α<sub>4</sub> subunit
William Wisden, Anne Herb, H. Wieland et al. · FEBS Letters · 1991 · 259 citations
Life Sciences, Neuroscience, Pharmacology +16
Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents
H. Wieland, W. Engel, Wolfgang Eberlein et al. · British Journal of Pharmacology · 1998 · 258 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +14
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group
Thomas Beckers, Carmen Burkhardt, H. Wieland et al. · International Journal of Cancer · 2007 · 194 citations · Full text
Medicine, Oncology, Pharmacology +8
1–5 of 44